Leucid Bio is a clinical stage biotech company that specializes in developing next-generation Chimeric Antigen Receptor T-cell (CAR-T) therapies. Their mission is to improve treatment outcomes and save the lives of patients with refractory cancers by utilizing their proprietary Lateral CAR Platform. Founded in 2014, Leucid Bio has built upon 20 years of pioneering CAR-T research led by Dr.

John Maher at King's College London. The unique Lateral CAR platform developed by Leucid Bio enhances the performance of CAR-T therapies in pre-clinical studies. By adopting a natural biological configuration and moving key functional components into their natural position, these CAR-Ts consistently outperform previous generations.

This approach enhances T-cell potency, generates a persistent long-term response, and reduces toxicity. With its headquarters in London, UK, Leucid Bio operates at Guy's Hospital, utilizing state-of-the-art GMP manufacturing and clinical lab facilities. The company is backed by leading investors and has raised a total of £15 million in funding.

The dedicated and experienced executive team, led by Chairman Ian Miscampbell and CEO Filippo Petti, is committed to safely and effectively treating hard-to-treat cancers and developing better cell therapies for patients